Anteris Technologies Global prices $200M public offering and concurrent $90M Medtronic placement

Anteris Technologies Global (AMEUF [https://seekingalpha.com/symbol/AMEUF]) (AVR [https://seekingalpha.com/symbol/AVR]) announced the pricing of its public offering of 34,782,609 shares at $5.75 per share, to raise about $200 million [https://seekingalpha.com/pr/20370642-anteris-technologies-global-corp-announces-pricing-of-200-million-public-offering] from this offering, before deductions.

The offering is set to close on January 22, 2026, pending standard closing conditions.

All shares are being sold by the company, which has also given underwriters a 30-day option to buy an additional 5,217,391 shares at the same price, minus discounts and commissions.

In addition, Anteris has agreed to sell up to $90 million of its common stock to Medtronic plc through a subsidiary, following a stock purchase agreement from January 20, 2026.

This private placement is exempt from certain registration requirements and requires Medtronic to purchase at least 16% and no more than 19.99% of shares available after a public offering.

The completion of this private placement depends on the public offering, but not vice versa.

Anteris plans to use the proceeds from the offering, along with existing funds and the private placement, to support its growth strategy. This includes advancing the DurAVR® THV trial, expanding manufacturing, funding research for v2vmedtech, and the balance allocated to working capital and other general corporate purposes.

MORE ON ANTERIS TECHNOLOGIES GLOBAL CORP.

* Seeking Alpha’s Quant Rating on Anteris Technologies Global Corp. [https://seekingalpha.com/symbol/AVR/ratings/quant-ratings]
* Historical earnings data for Anteris Technologies Global Corp. [https://seekingalpha.com/symbol/AVR/earnings]
* Financial information for Anteris Technologies Global Corp. [https://seekingalpha.com/symbol/AVR/income-statement]